Clinical Situation: Newly Diagnosed

First-line treatment

First-line treatment with/without extended (maintenance) treatment

First-line treatment

For more detailed information, please click on the clinical trial ID number.

Drug Class Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Standard of Care Chemotherapy
Chemotherapy GOG-158 III Cisplatin, Carboplatin, Paclitaxel Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study.

No PFS or OS difference between cisplatin+paclitaxel and carboplatin+paclitaxel in optimally debulked stage III patients

CisPt+Pac vs CarboPt+Pac:

PFS: 19.4 vs 20.7 months
OS: 48.7 vs 57.4 months

v. 6/2018

Chemotherapy GOG-172 III Cisplatin, Paclitaxel Randomized phase III study of intravenous (IV) paclitaxel and cisplatin vs. IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172).

PFS and OS increased with IP treatment in optimally debulked stage III patients, but IP had more severe side effects

CisPt+Pac (IV) vs CisPt+Pac (IP):

PFS: 18.3 vs 23.8 months*
OS: 49.7 vs 65.6 months*

v. 6/2018

Chemotherapy NCT00326456 III Carboplatin, Liposomal doxorubicin, Paclitaxel Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer

No significant PFS or OS difference when paclitaxel or liposomal doxorubicin is added to carboplatin, but different toxicity profiles

CarboPt+Pac vs CarboPt+PLD:

PFS: 16.8 vs 19.0 months
OS: 53.2 vs 61.6 months

v. 10/2018

*Statistically significant result

First-line treatment with/without extended (maintenance) treatment

For more detailed information, please click on the clinical trial ID number.

Drug Class Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Standard of Care Targeted Drugs
Angiogenesis Inhibitors: VEGF NCT00262847 III Bevacizumab, Carboplatin, Paclitaxel A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (GOG218)

Improved PFS with addition of bevacizumab to carboplatin+paclitaxel in high risk patients, particularly those with ascites

CarboPt+Bev w/ Bev maint vs CarboPt+Bev vs CarboPt:

All:
PFS: 14.1 vs 11.2 vs 10.3 months*
OS: 43.3 vs 40.8 vs 41.1 months
With ascites:
PFS: 15.2 vs 10.3 months*
OS: 43.3 vs 39.9 months*

v. 6/2018

Angiogenesis Inhibitors: VEGF NCT00483782 III Bevacizumab, Carboplatin, Paclitaxel ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer

Improved PFS and OS with addition of bevacizumab to carboplatin+paclitaxel in high risk patients

CarboPt+Bev w/ Bev maint vs CarboPt:

All:
PFS: 19.9 vs 17.5 months
OS: 45.5 vs 44.6 months (restricted mean survival)
High risk:
PFS: 16.0 vs 10.5 months*
OS: 39.3 vs 34.5 months* (restricted mean survival)

v. 4/2018

*Statistically significant result

< Return to Clinical Situation

< Return to Clinical Trial Results Homepage